MARKETS / NYSE / PBH

NYSE · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Prestige Consumer Healthcare Inc. PBH

17 fiscal years on record · USD · FY2025 reported · SEC filings only

Revenue

$1.1B

▼ 4.3% YoY

Net income

$190.3M

▼ 11.3% YoY

Free cash flow

$246.4M

▲ 1.3% YoY

In brief

What this company does

Prestige Consumer Healthcare Inc. develops, manufactures, markets, sells and distributes brand name, over-the-counter health and personal care products to mass merchandisers, drug and drug wholesale, food, dollar, convenience and club stores and e-commerce channels in North America and in Australia and certain other international markets. It conducts its operations in two reportable segments: North American OTC Healthcare and International OTC Healthcare. Walmart accounted for approximately 20% of its gross revenues during fiscal 2026. Its major brands accounted for approximately 83.5% of its total revenues for fiscal 2026. It was formed as a Delaware corporation in 1996. Prior to August 17, 2018, the Company's name was Prestige Brands Holdings, Inc.

Written from the business description in Prestige Consumer Healthcare Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 14 May 2026. Every sentence was checked against that document before publication.

Growth

USD 1.1B

Revenue, FY2025 · full 17-year series below

Revenue $B Net income $B

FY2025 · Revenue 1.1 · Net income 0.2

Compound annual growth

Revenue

−1.2%

+2.9%

+3.0%

+8.1%

Net income

+2.9%

+6.7%

+13.3%

EPS, diluted

+3.8%

+7.6%

+13.6%

Returned to shareholders

+52.8%

+75.9%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at +2.9% a year over five years — but profit grew faster: net income at +2.9%, earnings per share at +3.8%.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

17 cents

of every revenue dollar became profit

Operating margin Net margin

FY2025 · Operating 28.4% · Net 17.5%

ROE

FY2025 · ROE 10.2%

Gross margin54.7%

Operating margin28.4%

Net margin17.5%

Return on assets5.5%

EBITDAUSD 340.7M

Each USD of equity produced 10 cents of profit this year.

Cash & shareholders

USD 152.0M

returned in FY2025 · dividends + net buybacks

Free cash flow $M

FY2025 · FCF 246.4

Net buybacks $M Dividends $M

FY2025 · Dividends — · Net buybacks 152.0

Dividends paid—

Net buybacksUSD 152.0M

Share of profit79.9%

Consecutive raises—

USD 152.0M in buybacks — 80% of the year's profit went back to shareholders.

Total assetsUSD 3.5B

EquityUSD 1.9B

CashUSD 63.9M

Gross debtUSD 994.0M

Net debtUSD 930.1M

Current ratio3.57×

Net debt stands at 49% of equity.

The 17-year record

17 fiscal years

Every figure from documents filed with the SEC · USD

row low → row highnegative

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
Revenue $B	1.1	1.1	1.1	1.1	1.1	0.9	1.0	1.0	1.0	0.9	0.8	0.7	0.6	0.6	0.4	0.3	0.3
Operating income $B	0.3	0.3	0.3	−0.0	0.3	0.3	0.3	0.1	0.2	0.2	0.3	0.2	0.2	0.2	0.1	0.1	0.1
EBITDA $B	0.3	0.4	0.4	0.0	0.4	0.3	0.3	0.1	0.2	0.2	0.3	0.2	0.2	0.2	0.1	0.1	0.1
Income tax $B	0.1	0.1	0.1	−0.0	0.1	0.0	0.0	−0.0	−0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0
Net income $B	0.2	0.2	0.2	−0.1	0.2	0.2	0.1	−0.0	0.3	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0
Free cash flow $B	0.2	0.2	0.2	0.2	0.3	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.1	0.1	0.1	0.1	0.1
EPS, diluted $	3.91	4.29	4.17	−1.65	4.04	3.25	2.78	−0.69	6.34	1.30	1.88	1.49	1.39	1.27	0.73	0.58	0.64
Dividend / sh $	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·	·
Payout %	·	·	·	·	·	·	·	·	·	·	0	0	0	0	·	·	·
ROE %	10.2	12.3	13.5	−5.4	14.0	13.0	12.6	−3.1	33.9	8.9	14.6	13.1	13.9	14.9	9.7	8.5	9.8

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance

Company facts, as filed

How we verify · 0 failures in 77 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 18 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures

ActivityPharmaceutical Preparations

Listed onNYSE

Incorporated innot stated in the filings

Fiscal year endsMarch 31

Data on record since2009